Literature DB >> 27847016

Low prevalence of hepatitis B and C among tuberculosis patients in Duhok Province, Kurdistan: Are HBsAg and anti-HCV prerequisite screening parameters in tuberculosis control program?

Muayad A Merza1, Safer M Haji2, Abid Mohialdeen Hasan Alsharafani2, Shivan U Muhammed2.   

Abstract

OBJECTIVE/
BACKGROUND: Viral hepatitis, particularly hepatitis B virus (HBV) and hepatitis C virus (HCV), infections and tuberculosis (TB) are a global public health concern. Co-infection with HBV or HCV among TB patients may potentiate the risk of hepatotoxicity induced by anti-TB drugs. Hence, the aim of this study was to identify the prevalence of HBV and HCV among TB patients included in the Duhok National Tuberculosis Program (NTP).
METHODS: The Duhok NTP Center is a specialized institution in Duhok City, Iraq, concerned with management and follow-up of TB patients. A cross-sectional study was conducted at the center between June 2015 and May 2016. All documented TB patients were analyzed on the basis of socio-demographic and other characteristics. Thereafter, all patients underwent screening for hepatitis B surface antigen (HBsAg), anti-HCV, and anti-HIV using enzyme-linked immunosorbent assay (ELISA). The results obtained were analyzed by entering the data in binary format into a Microsoft Excel spreadsheet. A p value of <.05 was considered to be statistically significant.
RESULTS: Two-hundred fourteen documented TB patients were recruited in this study, with 127 (59.3%) males and 87 (40.7%) females. The mean age of the patients was 40.34years (±20.29). Of the total number of patients, four cases (1.8%) were HBsAg-positive and one case (0.9%) was positive for anti-HCV. The variables significantly associated with HBV were history of surgical dental procedure [odds ratio (OR), 0.04; 95% confidence interval (CI), -0.01 to 0.04; p=.03], and nationality (OR, 13.67; 95% CI, 0.46-210.85; p=.007).
CONCLUSION: The prevalence of HBV and HCV co-infection among TB patients in this study was low. This may be explained by the low rate of blood transfusion among the patients, the very low prevalence of HIV infections in Kurdistan, the negative history of injection drug use, and adherence to universal infection-control measures, including vaccination for HBV. Both history of dental intervention and belonging to a Syrian population were independent risk factors for HBV/TB co-infection.
Copyright © 2016 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HBV; HCV; Prevalence; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27847016     DOI: 10.1016/j.ijmyco.2016.06.019

Source DB:  PubMed          Journal:  Int J Mycobacteriol        ISSN: 2212-5531


  5 in total

1.  Seroprevalence and Associated Factors of Hepatitis B and C Virus Among Pulmonary Tuberculosis Patients Attending Health Facilities in Gondar Town, Northwest Ethiopia.

Authors:  Birhanu Getie; Getnet Ayalew; Anteneh Amsalu; Getachew Ferede; Gizachew Yismaw; Belay Tessema
Journal:  Infect Drug Resist       Date:  2021-09-03       Impact factor: 4.003

2.  Seroprevalence and risk factors of hepatitis B and C viruses among diabetes mellitus patients in Duhok province, Iraqi Kurdistan.

Authors:  Muayad A Merza
Journal:  J Family Med Prim Care       Date:  2020-02-28

3.  Risk factors of hepatitis B virus infection among blood donors in Duhok city, Kurdistan Region, Iraq.

Authors:  Nawfal R Hussein
Journal:  Caspian J Intern Med       Date:  2018

4.  Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis.

Authors:  Meysam Behzadifar; Sanaz Heydarvand; Masoud Behzadifar; Nicola Luigi Bragazzi
Journal:  Ethiop J Health Sci       Date:  2019-01

5.  Hepatitis C Virus Affects Tuberculosis-Specific T Cells in HIV-Negative Patients.

Authors:  Mohamed Ahmed El-Mokhtar; Sherein G Elgendy; Abeer Sharaf Eldin; Elham Ahmed Hassan; Ali Abdel Azeem Hasan; Muhamad R Abdel Hameed; Douaa Sayed; Eman H Salama
Journal:  Viruses       Date:  2020-01-15       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.